From Genes to Treatments: A Systematic Review of the Pharmacogenetics in Smoking Cessation
Year: 2018
Type: review
Study design: Systematic Review
Abstract: Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.
Source: Pharmacogenomics
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Massachusetts General Hospital, Washington University in St. Louis, National Institutes of Health, National Institute on Drug Abuse, National Cancer Institute, National Center for Research Resources, National Center for Advancing Translational Sciences, National Institute on Minority Health and Health Disparities
Awards: Washington University Institute of Clinical and Translational Sciences, Genetic and Environmental Risks for Smoking Characteristics and Cessation, Stanford Precision Health for Ethnic and Racial Equity (SPHERE) Transdisciplinary Collaborative Center, Genetically Informed Smoking Cessation Trial, Washington University Institute of Clinical and Translational Sciences (KL2), Washington University Institute of Clinical and Translational Sciences (KL2), Cancer Center Support Grant
OpenAlex ID: W2809661506